Earnings Preview: Integra LifeSciences (IART) Q2 Earnings Expected to Decline
Bullish Integra LifeSciences Holdings Insiders Loaded Up On US$2.50m Of Stock
Integra LifeSciences Is Maintained at Hold by Truist Securities
Integra LifeSciences Price Target Raised to $32.00/Share From $25.00 by Truist Securities
A Quick Look at Today's Ratings for Integra Lifesciences(IART.US), With a Forecast Between $26 to $48
Integra Lifesciences: Strategic Manufacturing Shifts Amid Supply Constraints – A Hold Rating Perspective
Express News | Integra Lifesciences Holdings Corp : Truist Securities Raises Target Price to $32 From $25
Integra LifeSciences Holdings' (NASDAQ:IART) Earnings Have Declined Over Three Years, Contributing to Shareholders 54% Loss
Truist Raises Price Target on Integra LifeSciences Holdings to $32 From $25, Maintains Hold Rating
Integra Lifesciences Sell Rating Justified by Production Delays and Overvalued Stock
8 Analysts Have This To Say About Integra Lifesciences
Integra LifeSciences Is Maintained at Underweight by Morgan Stanley
Integra LifeSciences to Shift PriMatrix, SurgiMend Production to New Braintree, Massachusetts Facility by 2026
Express News | Integra Lifesciences : Morgan Stanley Raises Target Price to $27.00 From $24.00
Morgan Stanley Maintains Integra Lifesciences(IART.US) With Sell Rating, Cuts Target Price to $27
Express News | Integra Lifesciences Holdings Corp -Expects to Operationalize This New Facility in First Half of 2026
Express News | Integra Lifesciences Holdings Corp - Plans to Restart Manufacture of Primatrix, Surgimend at Facility in Braintree, Massachusetts
Express News | Integra Lifesciences Provides Updated Plans for Its Manufacturing Facility in Braintree, Massachusetts
Integra LifeSciences to Host Second Quarter 2024 Financial Results Conference Call on July 29, 2024
Morgan Stanley Raises Price Target on Integra LifeSciences to $27 From $24, Keeps Underweight Rating